At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
SER120 Nasal Spray 500 ng/day +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥ 75 Years Old) With Nocturia
In Brief
A Phase 3 clinical trial evaluating SER120 Nasal Spray 500 ng/day and SER120 nasal spray 750 ng/day for Nocturia. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
Primary CompletionNov 2010
First PostedDec 2010
TodayJul 2026
First PostedDec 13, 2010
Enrollment StartApr 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.6 years ago
Interventions
SER120 Nasal Spray 500 ng/daydrug
SER120 Level 1
SER120 nasal spray 750 ng/daydrug
SER120 (750 ng/day)